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Abstract 
Influenza disease epidemics occur seasonally in the United States and cause 
significant morbidity and mortality among certain high-risk groups. Influenza 
vaccines have been shown to decrease mortality and morbidity from influenza 
infection and are a safe and effective means of influenza prevention. Despite the 
availability of vaccine many high-risk groups are not vaccinated annually as is 
recommended by public health and medical experts. Lack of predictable, 
widespread vaccine uptake contributes to production and market issues affecting 
a consistently adequate and timely influenza vaccine supply. Problems with 
vaccine production in general are exacerbated by unique qualities of influenza 
vaccine production. Added to these problems is the urgent need to prepare for an 
impending influenza pandemic. Addressing these issues will involve public 
education and promotion of influenza vaccine, research and development of new 
vaccine technology and government intervention to assure a safe and adequate 
influenza vaccine supply. 
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Influenza Disease 
Influenza is a contagious, viral respiratory infection characterized by fever, 
dry cough, sore throat, extreme fatigue, headache, nasal congestion and body 
aches (Centers for Disease Control and Prevention [CDC], 2005). Duration of the 
illness is most commonly 2-7 days however cough and malaise can continue for 
two weeks or more. Person to person spread occurs primarily via large 
respiratory droplets. Incubation period is short, from 1-3 days. The period of 
communicability for adults is probably 3-5 days from onset of symptoms and up 
to 7 days from clinical onset for children (Heymann, 2004, p. 283). Studies have 
shown that influenza viruses can live for 24 to 48 hours on nonporous 
environmental surfaces and less than 12 hours on porous surfaces. This 
indicates that transmission can occur when hands that touch contaminated · 
surfaces subsequently come into contact with oral, ocular, or nasal mucosa. 
Fomite transmission appears to be rare (Bean, et. al., 1982). 
Complications of influenza can include pneumonia, secondary bacterial 
infections, and exacerbation of underlying chronic heart or lung disease and 
death. An estimated average of 36, 000 Americans die annually from influenza 
and 200,000 hospitalizations are attributed to this infection. (Thompson, et.al, 
2003, 2004) In those aged greater than 65 years, influenza related deaths range 
from between 30 and 150 per 100,000 (World Health Organization [WHO], 2005). 
Groups more likely to suffer complications or severe disease are the elderly, very 
young children and those with chronic cardiac, pulmonary, renal, and metabolic 
disease and anemia or a compromised immune system (Heymann, 2004). 
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Treatment of influenza is largely palliative although there are antiviral 
medications that can be used successfully to mitigate symptoms and/or shorten 
the course of the illness by 1.5-2.5 days. Currently there are two classes of 
antiviral medication available for treatment of influenza. These are adamantanes 
or M2 ion channel inhibitors (i.e.amantadine and rimantadine) and neuraminidase 
inhibitors (i.e.oseltamivir and zanamivir). Adamantanes are effective only against 
influenza A. These drugs may be used for treatment or chemoprophylaxis for 
influenza A. The neuraminidase inhibitors are effective against both influenza A 
and B but are not approved in the U.S. for preventive treatment. The treatment 
for influenza infection must be initiated as soon as possible and within 48 hours 
after symptoms begin to be effective (Stiver, 2003). These medications are very 
useful in outbreak situations and for prophylaxis treatment for high-risk 
individuals. Recently one of the antiviral medications used to treat influenza, 
adamantine, was found to be ineffective because high levels of drug resistance 
had developed in the influenza A (H3N2) viruses. The CDC issued an alert to 
medical providers to use one of the other antiviral drugs (CDC, 2006). This 
development emphasizes the need for prevention of influenza and the focus on 
influenza vaccination as the foundation of a successful influenza prevention 
campaign (CDC, 2005). 
An unstable virus. Two types of influenza virus cause epidemic human 
disease, influenza A and influenza B. Influenza A viruses cause large epidemics 
with high mortality. Influenza A is further classified into subtypes based on the 
surface antigens hemagglutinin (H) and neuraminidase (N). Influenza A (H1 N3) 
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and (H3N2) viruses have been circulating worldwide since 1977. Both influenza 
A and B undergo genetic reassortment (antigenic drift), although influenza B 
viruses undergo these changes less rapidly than influenza A. These minor 
genetic changes that occur during viral replication produce virus variants that 
result in the need for seasonal changes in the influenza vaccine to match as 
closely as possible the circulating strains. (CDC, 2005). 
Antigenic shift is a major genetic change in the virus, resulting in a new 
viral strain to which humans have little to no immunity. Proteins on the surface of 
the virus recombine as a result of mutation or exchange of genetic material 
between multiple influenza viruses. This dramatic mutation of influenza virus has 
historically caused flu pandemics. These flu pandemics have all been caused by 
·influenza A viruses. Potential pandemic strains must have an antigenic makeup 
to which the population has no immunity, be able to replicate in humans, and 
efficiently transmit from human to human. New pandemic strains are most likely 
to be of subtypes not previously recognized in human populations. Currently, 
strains of H5 and H7 subtypes are of greatest concern (Centers for Infectious 
Disease Research and Policy, 2005). 
The following table outlines differences between seasonal influenza and 
pandemic influenza. 
Assuring the Influenza Vaccine Supply 5 
Table 1 
Seasonal Influenza Pandemic Influenza 
Outbreaks follow predictable seasonal Occurs rarely (three times in 20m 
patterns; occurs annually, usually in century-last in 1968) 
winter, in temperate climates 
Usually some immunity built up from No previous exposure; little or no pre-
previous exposure existing immunity 
Healthy adults usually not at risk for Healthy people may be at increased 
serious complications; the very young, risk for serious complications 
the elderly and those with certain 
underlying health conditions at 
increased risk of serious complications 
Health systems can usually meet public Health systems may be overwhelmed 
and patient needs 
Vaccine developed based on known flu Vaccine probably would not be 
strains and available for annual flu available in the early stages of a 
season pandemic 
Adequate supplies of antivirals are Effective antivirals may be in limited 
usually available supply ' 
Average U.S. deaths approximately Number of deaths could be quite high 
36,000/yr (e.g., U.S. 1918 death toll 
approximately 500,000) 
Symptoms: fever, cough, runny nose, Symptoms may be more severe and 
muscle pain. Deaths often caused by complications more frequent 
complications, such as pneumonia. 
Generally causes modest impact on May cause major impact on society 
society (e.g., some school closing, (e.g. widespread restrictions on travel, 
encouragement of people who are sick closings of schools and businesses, 
to stay home) cancellation of larqe public qatherings) 
Manageable impact on domestic and Potential for severe impact on domestic 
world economy and world economy 
Note. From CDC website, http://www.pandemicflu.gov/season or pandemic.html 
Retrieved March 5, 2006. 
Disease surveillance. Unlike many communicable diseases, physicians 
and laboratories are not required to report individual cases of influenza to the 
health authorities. Surveillance for influenza in the U.S. is accomplished through 
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a system that includes World Health Organization (WHO) and National 
Respiratory and Enteric Virus Surveillance System (NREVSS) laboratories, a 
network of approximately 1500 sentinel sites that report influenza-like illness (Ill) 
patient visits, the percentage of U.S. deaths attributable to pneumonia and 
influenza (P&I) reported through the 122 Cities Mortality Reporting System and 
estimated levels of influenza reported to the Centers for Disease Control and 
Prevention (CDC) by state and territorial epidemiologists. The U.S. Influenza 
Sentinel Providers Surveillance Network includes physicians, hospitals, university 
health centers and public health agencies. These participants report Ill data to 
CDC each week and collect representative samples for virus strain identification. 
The case definition of Ill for these surveillance purposes is a fever of 100 
degrees F or higher and cough or sore throat. Significant outbreaks of influenza, 
as well as reports of severe illness and death are also reported to the CDC by 
local health officials. (CDC, 2003,2005). This system of disease reporting allows 
the CDC and local and state health officials to monitor influenza activity in the 
nation. 
Economic burden of disease. Total economic costs associated with 
influenza disease are difficult to calculate for various reasons. In many cases 
influenza infection is not confirmed in persons seen at a medical practice or 
admitted to the hospital. A diagnosis is made based on clinical symptoms and is 
not always confirmed by laboratory testing. The laboratory tests are often costly 
and are most often used for surveillance and in outbreak situations (Blitz, Cram, 
Manto, Fendrick, 2002). Many individuals who lose work or school days to 
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influenza infection may not been seen at a medical provider because of lack of 
health care coverage or if symptoms are relatively mild. However, it is estimated 
that approximately 62 million people restrict their work or school activities or seek 
medical care for influenza-like illness every year (AHA, 2004). Studies have been 
done to assess the burden to families of influenza disease in children. Prinicipi 
and Esposito (2004) reviewed studies that concluded that prevention of influenza 
in otherwise healthy school-aged children would have significant effects on the 
families. Results would include fewer missed workdays for adults and fewer 
hospitalizations and medical visits for the children and their household contacts. 
Because school-aged children are considered an important source of community-
wide transmission of influenza, some experts have recommended mass 
vaccination of school-aged children to reduce the impact of influenza in the 
community (White, Lavoie, Nettleman, 1999; Halloran& Longini 2006). 
A 2001 study of the economic burden of influenza-like illness (Ill) in long-
term-care facilities in Virginia demonstrated the substantial cost associated with 
Ill. In the four facilities studied for the 1998-99 influenza season the mean costs 
for each case was between $968 and $1341, not including the cost of 
prophylaxis for asymptomatic resident contacts (Carroll et.al, 2001 ). 
The most common complication of influenza is pneumonia. Since 
influenza may be confused with other respiratory infections and may not be 
laboratory confirmed in many cases, the mortality associated with influenza is 
often calculated in terms of excess deaths from pneumonia (WHO, 2005). A 
study by the Connecticut Department of Public Health estimated the economic 
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cost of influenza and pneumonia in their state in 1998 to be 170 million dollars in 
hospital admissions alone. The cost of influenza epidemics in the United States 
is estimated to be 12 billion annually (Bower, 2000). 
Influenza vaccine 
Influenza vaccines have been available for more than sixty years (WHO, 
2002). Inactivated influenza vaccine is composed of antigens matching the two 
currently circulating wild influenza A viruses and an influenza B virus. Thus the 
vaccine is labeled a trivalent vaccine, protecting against three viral strains. 
Surveillance is used in the tropical regions of the world to determine which 
viruses are circulating and are likely to cause epidemic disease in the world's 
temperate zones. The antigens are made non-infectious or "killed" in order to 
promote immunogenic protection without producing disease. There are three 
types of killed influenza virus vaccines: whole virus, split and subunit virus 
vaccines. Most industrialized countries use the split or subunit virus because it 
causes fewer vaccine reactions (WHO, 2005). 
A live, attenuated influenza vaccine (LAIV) was approved for use in the 
United States in June 2003. The vaccine is currently approved for use in healthy, 
non-pregnant individuals aged 5-49 years. This vaccine, Flu Mist TM, produced by 
Medimune, Inc. of Maryland, is administered intranasally. The efficacy of the 
vaccine was studied and found not to be significantly different from the 
inactivated influenza vaccine. Benefits of the LAIV are the vaccine's potential to 
induce a broad mucosal and systemic immune response and administration by 
nasal spray rather than intramuscular injection. Drawbacks include storage 
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limitations (must be kept frozen prior to administration) and higher cost than the 
injectable vaccine (CDC, 2003). Obviously, the most important disadvantage to 
this vaccine is that it cannot be used to vaccinate high-risk individuals. 
Vaccine efficacy. No vaccine is 100 % effective in all individuals. Various 
factors influence the efficacy of the influenza vaccine. Most important is the 
accuracy of the match between the viral antigens contained in the vaccine and 
the particular pathogen to which the person is exposed. Factors contributing to 
the effectiveness of the vaccine include age and health status of the vaccinee 
and the accuracy of the diagnosis. In approximately 70-90% of healthy adults the 
trivalent vaccine will prevent laboratory confirmed illness (WHO, 2005). It is 
expected that those with compromised immune systems will experience less 
efficacy with vaccination. The Advisory Committee on Immunization Practices 
estimated only a 30-40% efficacy rate in the frail elderly (CDC, 1997). Trivalent 
influenza vaccines (TIVs) have been shown to be highly effective in children 
greater than 6 years old but demonstrate poor efficacy in children less than 2 
years. There is no licensed influenza vaccine for infants less than 6 months old. 
Children less than 36 months old receive one-half the adult dose of vaccine and 
children aged less than nine years should receive two doses of vaccine 
administered one month apart. TIV can be administered at the same time as 
other recommended childhood vaccines. 
Vaccine administration recommendations. The Advisory Committee on 
Immunization Practices (ACIP) is a group of experts selected by the Secretary of 
the U.S. Department of Health and Human Services to provide advice and 
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guidance on the most effective means to prevent vaccine-preventable diseases. 
This information is formalized via written recommendations for the administration 
dosage, schedule, and vaccine contraindications for pediatric and adult 
populations (CDC, NIP, n.d.). As data is gathered regarding morbidity and 
mortality attributed to influenza or Ill, new groups may be added to those 
recommended for influenza immunization. These guidelines are designed to 
provide vaccine coverage for groups at high risk for serious complications from 
influenza infection. This determination is based on influenza associated 
hospitalization rates and mortality. Included in the priority groups currently are 
contacts to high-risk persons including health-care workers and household 
contacts of children less than 6 months old (CDC, 2005). 
Vaccine manufacturing. The manufacturing process for the influenza 
vaccine is a very complex process and is different than that of many other 
vaccines. As noted previously, the influenza vaccine changes or has the potential 
to change every year in order to match the strains of circulating influenza viruses. 
The vaccine cannot be stored but excess doses must be destroyed or disposed 
of after the end of the vaccination season. 
Cultivation and development of the vaccine is very labor intensive and 
time consuming. Production time from start to delivery is approximately ten 
months (CDC, 2004). The virus is cultivated and grown in fertilized chicken eggs. 
The high-yield donor virus is in inoculated into the eggs and incubated for several 
days. One dose of vaccine is produced from one or two eggs (GSK, 2005). 
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The vaccine must be designed, developed, tested and ready for delivery in 
a short period of time. The influenza vaccine must be delivered to providers by 
October in order to be used to vaccinate high-risk individuals. In the United 
States influenza season runs from November to March. The time between 
vaccination and development of antibodies is approximately two weeks. 
Market factors. Vaccine manufacturing is not as profitable as other 
pharmaceutical products. Medications are used far more frequently than 
vaccines and vaccine prices are strongly influenced by the federal government. 
The federal government, at a significantly lower price than private purchasers 
· pay, purchases fifty-two percent of the childhood vaccines used in the U.S. This 
combination of factors has contributed to the abandonment of vaccine 
manufacture by many pharmaceutical companies (Cohen, 2002). 
Influenza vaccine production is largely based on the previous year's 
demand. This number can be variable and related to actual or perceived 
influenza activity, media reporting of deaths from influenza, etc. Few 
pharmaceutical countries in the United States produce influenza vaccine. 
Vaccines produced in other countries must be approved and licensed by the FDA 
for use in this country. 
Influenza Vaccine Delivery and Distribution 
Problems with influenza vaccine delivery and distribution were evident in 
the 2000 and the 2001 influenza vaccination season. In 2000 problems with 
vaccine manufacturing, including difficulty with one manufacturer growing one of 
the viral strains and two manufacturer's regulatory problems with the Food and 
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Drug Administration (FDA) combined to create a significant delay in vaccine 
delivery. The decision in 2000 by one pharmaceutical company to permanently 
discontinue the manufacture of influenza vaccine along with continued regulatory 
problems with two pharmaceutical companies led to another less severe delay in 
delivery of influenza vaccine in 2001. While many in the public perceived these 
delays as shortages, they were not true shortages as the number of doses of 
influenza vaccine manufactured closely approximated the expected number. 
However many providers did not receive vaccine delivery during peak times of 
high demand. A major concern of many physicians and other community 
members was the uneven distribution pattern that allowed grocery store chains 
and other non-medical organizations to receive vaccine before hospitals, nursing 
homes and physicians offices (Fukuda, O'Mara & Singleton, 2002). One study in 
Tennessee surveyed elderly residents and found that the vaccine delay resulted 
in changes in the location where the flu shot was obtained but did not change 
vaccination rates in the patient sample (Santibanez, Nowalk, Zimmerman, 
Bruehlman, 2003). 
A true influenza vaccine shortage emerged in October 2004 though it may 
not have been as extreme as widely reported. The U.S. pharmaceutical 
manufacturer, Chiron, announced that they would not be delivering the 
approximately 45 million expected doses of the influenza vaccine, Fluvirin. The 
Medicines and Healthcare products Regulatory Agency (MHRA) of the U.K. had 
suspended the manufacturing license for Fluvirin at the facility in Liverpool, U.K. 
Earlier in the fall of the year the company reported that in the final release 
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inspection they found bacterial contamination in a few lots of vaccine. This would 
mean a delay in vaccine delivery. The company completed internal investigations 
and submitted to reviews by the MHRA and expressed confidence that the 
problems were limited to the lots identified in August of 2004. However, on 
October 5, 2005 Chi ron received a letter stating their manufacturing license had 
been suspended for three months for failure to follow Good Manufacturing 
Practice regulations in their operations (Congressional Quarterly, 2004 ). 
The media reported that this loss of vaccine cut the nation's flu vaccine 
supply in half. While this was technically true, when Chi ron projected almost 50 
million doses would be supplied to the U.S. this was more flu vaccine than had 
ever been available in this country before (Brookes). The average number of 
doses ofinfluenza vaccine used in previous recent years ·ranged from between · 
70-80 mill ibn (Fukuda, 2002). With the doses supplied by the other licensed flu 
vaccine manufacturer, Aventis Pasteur, this created a supply for the U.S. market 
of almost 100 million doses. It is unclear if that many doses had been ordered or 
sold (Brookes). One study indicated that, based on immunization rates reported 
for high-priority groups in the 2002-2003 season, about 43 million doses would 
be enough to immunize the high-risk population in the U.S. in 2004(Treanor, 
2004 ). A report by the United States Government Accounting Office stated that 
for the 2002-2003 influenza season there were 95 million doses of vaccine 
produced. Of these, about 83 million doses were used (GAO, 2004 ). Ironically, 
just prior to the announcement that one of the two suppliers of flu vaccine in the 
U.S. would not be releasing their vaccine supply, federal and state officials had 
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made announcements expanding the recommendations for influenza vaccination. 
In the wake of the projected shortage these recommendations had to be 
restricted and vaccination limited to the priority groups defined by the CDC and 
ACIP (CDC, 2004). 
The following is the list of priority groups for vaccination with inactivated 
influenza vaccine as determined by the CDC and ACIP for the 2004-2005 
influenza season. 
• all children aged 6--23 months; 
• adults aged ::65 years; 
• persons aged 2--64 years with underlying chronic medical conditions; 
s all women who will be pregnant during the influenza season; 
~ residents of nursing homes and iong-term care facilities; 
• children aged 6 months--18 years on chronic aspirin therapy; 
• health-care workers involved in direct patient care; and 
• out-of-home caregivers and household contacts of children aged <6 
months (CDC, 2005). 
The live attenuated intranasal vaccine was promoted for those eligible to 
receive it. The recommendation included health care workers with direct patient 
contact Because it is a live virus vaccine, there is the potential of virus shedding 
by the vaccinee. The CDC and ACIP determined that only health care workers 
with direct patient contact with severely immunosuppressed patients should not 
receive the Flu Mist if they were otherwise eligible (CDC, 2003). 
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Affected populations. It was well documented in the media that the loss of the 
Chiron flu vaccine created severe problems in access for the most vulnerable 
populations, specifically elderly adults. Dramatic reports emerged of elderly 
patients waiting in lines for hours to be immunized. One elderly woman in 
California reportedly died after she fainted and fell during a four-hour wait for a flu 
shot (Boehm, 2004 ). 
The Harvard School of Public Health conducted a national survey to 
determine the experiences with obtaining influenza vaccination among persons in 
high priority groups during this shortage. Table two shows the results of the 
survey, that approximately 63% of those 65 and 46% of chronically ill adults who 
attempted to get a flu shot were s.uvcessful. Sixty-seven pE)rcent of the children 
aged 6-23 months who tried to obtain influen:;:a vaccination received the vaccine. 
Table 2 
1 Percentage of respondents who reported that they tried to get the influenza 
vaccine during the preceding 3 months, by priority group- Project on the Public 
and Biological Security, Harvard School of Public Health, United States, 2004 
Priority Group % (95%CI*) 
Persons aged 2: 65 years (n=242) 
Did not try to get vaccine 
Tried to get vaccine 
Could not get the vaccine 
Received the vaccine 
Persons with chronic illness (n=306) 
Did not try to get vaccine 
Tried to get vaccine 
Could not get the vaccine 
Received the vaccine 
Children aged 6-23 months (n=249) 
Did not try to get vaccine 
Tried to get vaccine 
Could not get the vaccine 
L Received the vaccine 
51 
49 
37 
63 
63 
37 
54 
46 
50 
50 
24 
76 
(42-59) 
(41-56) 
(28-46) 
(54-72) 
(56-70) 
(29-44) 
(45-69) 
(37-55) 
(39-59) 
(39-59) 
(16-32) 
(68-84) 
I 
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* Confidence Interval 
Note. From CDC Morbidity and Mortality Weekly Report (2004). 53(49): 1154. 
The influenza vaccine shortage affected physicians as they were forced to 
make decisions about who would or would not receive a flu vaccination. While 
the CDC had defined priority groups for vaccination controlling administration of 
private vaccine supplies was virtually impossible. Access to vaccine varied widely 
with reports of some low-risk individuals getting immunized with no questions 
asked to elderly persons waiting in line for up to nine hours ("Flu vaccine ", 
2004). 
Physicians Bernard Lo and Mitchell Katz (2005) developed an algorithm to 
guide clinical decision making during public health emergencies. 
Figure 1. Physician responses when patients disagree with public health 
guidelines in an emergency. 
Department of 
Public Health 
declares emergency 
Department of Public Health modifies and issues public 
health guidelines guidelines on the basis of experience and 
feedback from physician. 
Physician 
interacts with 
patient 
Patient expresses 
concerns to 
physician 
Patient agrees Patient 
I 
Physician 
I 
-
with public declines to 
health follow PH 
guidelines guidelines 
Physician attempts 
to persuade patient 
1 
Patient agrees Patient still I Phvsician refers case I with public declines to 
health follow PH 
guidelines guidelines I Public health measures may I he enforcecl hv no lice nower 
Dept. of 
Public 
Health 
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Note. From Clinical Decision Making during Public Health Emergencies: Ethical 
Considerations. Ann Intern Med. 2005; 143:493-498. 
Their conclusions state that while the medical provider may not be able to 
comply with the patient's request if it is contrary to public health guidelines the 
physician's responsibility remains as the patient's advocate, to address and 
acknowledge their needs and concerns (Lo & Katz, 2005). 
Hospitals and long-term care facilities faced similar ethical decisions 
during the vaccine shortage. Some hospitals confronted issues of defining 
"direct healthcare workers" and explaining to some staff why they were not 
chosen to receive vaccine (Healthcare Benchmarks, 2004 ). 
· · ' · :··Despite the confusion;. irconvenience and very serious consequences of 
the vaccine shortage crisis, it appears that in most cases the majority ,Jf high-risk 
·groups who wanted the vaccine were immunized (CDC, 2004). This can in large 
part be attributed to the public health response from the federal level to state and 
local health districts. The CDC coordinated distribution of available vaccine after 
the October 5th Chiron announcement (NAACHO, 2005). In most cases the state 
and local health departments became the "brokers" for the distribution of vaccine 
supplies to the most vulnerable citizens utilizing the secure Web-based database 
developed by the CDC and Aventis Pasteur. This information allowed states to 
determine vaccine distribution in the private sector and identify gaps and excess 
supplies (Congressional Quarterly, 2004 ). 
Public health agencies were challenged during this particular vaccination 
season. In many states public health agencies used disaster preparedness 
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plans to coordinate vaccine administration and secure doses of influenza vaccine 
for high-priority individuals (Bashir and Ransom, 2005). The public health 
infrastructure in many areas was burdened as workers were pulled from their 
usual jobs to respond to the flu vaccine shortage crisis. 
Tables 3 and 4 show some of the results of a web-based survey 
conducted by the National Association of County and City Health Officials to 
assess the response of their members to the flu vaccine crisis and the impact on 
the routine public health activities. 
Table 3 
k-. How Did Your Agency Respond to the Shortage? 
'Act1on % of LPHAs Responding · ~~---
I Held late-season influenza clinics -;c·-·-::-~-·-::-:---::-~-~~------· ._-_-__ -. ~ ! Exercised and implem-ented -:----:-::~ 
I preparedness plans, including _ 
-- . - . I i conducting mass vaccination clinics - · ,· ' ·- . . 
I Rescheduled previously planned clinics 9 
I Cancelled clinics 39 
Redistributed vaccine to local partners 38 
Formed flu coalitions/community 94 
partnerships 
Implemented priority schemes, 19 
including lotteries 
Other 11 
Table 4 
Impact on Other Local Public Health Services and Activities 
Action Delayed % of LPHAs Responding 
I Communicable disease investigations, 33 
including surveillance 
HIV/STD/TB testing, screening and 9 
services 
Inspections 6 
Family planning/WIG/nursing outreach 24 
services 
Administrative activities 30 
_Trainings 22 
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Note. From NAACHO Issue Brief. htto://archive.naccho.org/documents/lnfluenza-
lssue-Brief-June-2005-3.pdf. Retrieved February 2, 2006. 
Responses to vaccine shorlage. Unfortunately, there were some 
unsavory reactions to the flu vaccine shortage crisis. There were reports of price 
gouging, theft of vaccine and other drastic responses ("Flu vaccine", 2004). Many 
U.S. citizens traveled to Canada to obtain a flu shot (Brookes). 
The U.S. Department of Health and Human Services did purchase vaccine 
that was not licensed for use in this country. Glaxo Smith Kline provided 1.5 
million doses of Fluvarix, which was approved for use in Germany (GAO, 2005). 
For legal purposes the vaccine must be administered as an investigational drug 
and the recipient was required to signa waiver before the vaccine could be 
administered. In addition to the relatively late arrival of the vaccine, in December 
2004, reluctance by many citizens to sign the waiver and some citizens' concerns 
about safety meant that none of these doses were used (Desroches, et al, 2005, 
GAO, 2005). 
Prior to the eventual reallocation of sufficient flu vaccine to immunize the 
high-risk population, the dose-sparing strategies of using Y, of the adult dose and 
intradermal versus intramuscular injection were considered. These strategies had 
been studied previously and were found to have some validity (Treanor, et al., 
2002, Kenney, et al., 2004). 
In lieu of being vaccinated, persons not eligible for either the live virus 
intranasal vaccine or the inactivated vaccine were advised to use common-sense 
influenza prevention measures. Respiratory hygiene was stressed, as well as 
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frequent hand washing and staying home when ill (CDC, 2004, Healthcare 
Benchmarks, 2004 ). 
Local public health agencies as well as private providers grappled with 
distributing the limited vaccine to the priority groups (Brookes, 2005,). At the 
time, the CDC was not willing to further prioritize vaccine delivery within the 
defined groups. The problem did prompt the CDC to create an ethics committee 
to debate such questions of rationing of vaccine during times of extreme 
shortages or limited supply. 
In August 2005 the CDC and ACIP provided tiered recommendations for 
use by state and local health officials in the event of another vaccine shortage. 
The guidelines state that the groups in tier 1A should be vaccinated before · 
, - anyone in an extreme shortfall of vaccine. During less dramatic vaccine 
shortages all groups in tier 1 should be considered equivalent and should be. 
vaccinated first, followed by groups 2 and 3. 
Table 1 Priority Groups for Vaccination with Inactivated Influenza Vaccine 
Tier Priority Group 
1 A • Persons aged ~ 65 years with 
comorbid conditions 
• Residents of long-term-care 
facilities 
1 B • Persons aged 2-64 years with 
comorbid conditions 
• Persons aged ~ 65 years 
without comorbid conditions 
• Children aged 6-23 months 
• Pregnant women 
1 c • Health-care personnel 
• Household contacts and out-of-
home caregivers of children 
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aged < 6 months 
2 • Household contacts of children 
and adults at increased risk of 
influenza-related complications 
• Healthy persons aged 50-64 
years 
3 • Person aged 2-49 without high-
risk conditions 
Note. From MMWR Vol. 54 No. 30 
Discussion 
Increasing influenza vaccine uptake. One of the goals of Healthy People 
2010 is to increase the influenza immunization rate among high-risk populations, 
up to 90% of those over age 65 and up to 60% for other high-risk individuals 
{CDC, 2000). Data collected from national surveys indicate that vaccine uptake, 
even in times of sufficient supply and especially among those at highest risk is 
woefully inadequate. The following:tables illustrate the deficits in immunizing 
these high priority groups in the two previous influenza vaccination seasons. 
Table 5 
Selected Group 
Ages 18-49, High-risk 
Ages 50-64, High-risk 
Ages 50-64, Total 
Ages 65 and older 
Pregnant Women 
Health Care Workers 
Household Contacts 
Percentage Coverage 
24.2 
46.3 
36.8 
65.5 
12.8 
40.1 
18.9 
From the 2003 National Health Interview Survey, coverage level data for selected 
groups targeted for influenza vaccine (CDC, 2005). 
Table 6 
Selected Group 
Ages 18-64, High-risk 
Ages 65 and older 
Ages 6-23 Months 
Ages 2-17, High-risk 
Health Care Workers 
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Percentage Coverage 
25.5 
62.7 
48.4 
34.8 
35.7 
L _______________________________________________ ~ 
From the Behavioral Risk Factor Surveillance System (BRFSS), selected data 
collected during the 2004-05 influenza season (CDC, 2005). 
Health care workers. CDC has recommended mfluenza vaccination for 
healthcare workers (HCWs) wfth direct patient contaCt since "1984 and for all 
HCWs since 1993 (Talbot, et al, 2005). Despite this it is estimated that only 36-
40% of HCWs receive flu vaccine each year (CDC 2005). Vaccination of health 
care workers key in controlling influenza spread to high-risk individuals. 
Surveys of unvaccinated HCWs show that reasons for not receiving the 
vaccine reflect those cited by members of the general public. The reasons 
include, 1) procrastinated/forgot; 2) inconvenience; 3) concerns about adverse 
effects; 4) belief that the vaccine is ineffective; 5) fear of needles; and 6) belief 
that influenza is not a serious disease (Toy, Janosky & Laird, 2005; Roush, 2005; 
Zimmerman, et al). 
The Immunization Action Coalition, a non-profit organization, creates and 
distributes educational material for health professionals and the public that 
promote the safe and effective delivery of immunization services. Their stated 
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goal is to increase immunization rates and prevent disease. The following are 
steps outlined for health care institutions to establish an influenza vaccination 
program for their staff. The steps to include: 
}> Persuade top management to commit to an annual employee vaccination 
program. 
}> Make the vaccination program convenient for all employees. 
}> Offer vaccines free of charge to all staff-full-time, part-time, and 
volunteers. 
}> Develop campaigns to educate employees. 
}> Educate health care workers to be advocates for influenza vaccination. 
(Immunization Action Coalition, 2004). 
Vaccination of children. The CDC has recommended annual influenza 
immunization for high-risk children 6 months of age or older for almost 40 years 
(Rickert, Santoli, Shefer, Myrick, Yusuf, 2006). Although in the past the flu 
vaccine has not been recommended for healthy children, today vaccination of 
children 6-23 months of age is strongly recommended by the Advisory 
Committee on Immunization Practices. 
However, vaccination of high-risk children remains unacceptably low. 
Research has shown that medical provider recommendation is a strong motivator 
for receiving influenza vaccination (Mayo & Cobler, 2004 ). One study researched 
reasons that physician adherence to national recommendations to administer 
influenza vaccine to high-risk children remains low. Their findings suggest a 
combination of factors including lack of coordination of care among specialist and 
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generalists and a need for more organizational capacity for identifying and 
recalling high-risk patients (Rickert, Santoli, Shefer, Myrick, Yusuf, 2006). 
Of course parents are the target of educational interventions and 
recommendations related to immunization of children. Because children already 
are required to have numerous vaccines some parents avoid the influenza 
vaccine. A Denver study of five pediatric practices showed a substantial positive 
change in parental attitudes about influenza vaccination during the 2003-2004 flu 
season. This was attributed to an intensively publicized influenza outbreak and 
concurrent physician recommendation for vaccination (Daley, et al, 2006). 
Public education. Unfortunately the public underestimates flu as an illness. 
Experts agree that education is necessary to .achieve broader public 
understanding of the morbidity and mortality of influenza and the safety and 
efficacy of the flu vaccine (Zimmerman, et al, 2003). Education about all forms of 
influenza protection, including the nasal spray vaccine is necessary (DesRoches, 
Blendon & Benson, 2005). Some have suggested direct to consumer advertising 
to those aged 65 years and older would be a cost-effective method of promoting 
influenza immunization in this age group (Patel, et al, 2006). 
Assuring the vaccine supply. Concerns about the influenza vaccine supply 
have been an issue for several years. Shortages of other vaccines recently have 
heightened the fear of influenza vaccine shortfalls (Cohen, 2002). The influenza 
supply is even more precarious for reasons noted previously: 1) the varying 
demand for vaccine; 2) inability to stockpile vaccine beyond one influenza 
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season; 3) complexity of influenza vaccine development and 4) the dearth of 
manufacturers supplying flu vaccine. 
In 1993 the Institute of Medicine (10M) proposed the development of a 
National Vaccine Authority that involves the creation of a government-owned, 
contractor operated national vaccine facility (I OM, 2001 ). This authority would 
control production and distribution of all vaccines and monitor supply and 
demand. This plan is widely opposed by the pharmaceutical industry (Cohen, 
2002). 
There has been legislation introduced to address the problems of 
influenza vaccine supply. The Flu Protection Act introduced by Congressman 
Rahm Emanuel of Illinois in 2004 establishes funds for a influenza vaccine public · 
awareness campaign and provides tax incentives for companies to improve their 
production capacities. The measure also calls for funds for the creation of more 
vaccine companies with more rapid production capability, requires planning by 
the CDC for any future influenza vaccine shortages and calls for more accurate 
estimates of needed vaccine each year through greater cooperation between 
manufacturers and the federal government (US House of Representatives, 
2005). 
Senators Hillary Clinton of New York and Pat Roberts of Kansas 
introduced the Vaccine Security Act in 2005. Components of the bill include: 
• Market guarantees: 
o Health and Human Services would set annual targets for influenza 
vaccine production 
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o The Secretary authorized to stockpile and buyback vaccine and 
purchase antivirals 
o Companies wishing to participate in buyback program must supply 
information allowing CDC to track distribution of vaccine 
o Manufacturers must give 12 months notice to the Secretary before 
deliberately discontinuing influenza vaccine production 
o Regulatory assistance to manufacturers 
• Increased research into vaccine development alternatives 
o Additional financing for NIH research into alternatives such as cell-
based culture and permanent influenza vaccine 
o Establishment of county by county electronic vaccine tracking 
system 
o Development of medical personnel registry to help during 
emergencies including influenza vaccine shortages 
o Increased outreach and education on influenza vaccine 
• Pandemic vaccine liability 
o Liability protections for products specifically design for pandemic flu 
(U.S. Senate, 2005). 
Senator Richard Burr of North Carolina introduced the Pandemic Vaccine 
and Drug Development Act of 2005 to the U.S. Senate. On of the components of 
this bill is the creation of the Biomedical Advanced Research and Development 
Agency (BARDA). This legislation would support research and development in 
the vaccine industry among other measures (Kling, 2005). 
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None of the above mentioned legislation has been passed yet. All the 
proposals are designed to strengthen and organize the nation's influenza vaccine 
supply and distribution process. The increasing reports of Avian influenza and 
the prediction of an impending influenza pandemic have benefited the goal of 
overhauling this country's interpandemic flu vaccine infrastructure. As part of the 
National Pandemic Influenza Preparedness and Response Plan, the U. S. 
Department of Health and Human Services has awarded a $75 million grant to 
Sanofi Pasteur to develop cell-based rather than egg-based influenza vaccine 
technology. The plan also calls for a U.S. based manufacturing facility for the 
cell-based influenza vaccine (Kling). 
The cell-based technology has several advantages over the egg-based 
production of flu vaccine. This process avoids risks associated with the egg-
based technology: potential impurities in eggs that may cause sterility problems 
and allergies to egg albumin. The step of adapting the virus to grow in eggs is 
avoided. The procurement of millions of eggs and long timeline from inoculation 
to delivery is unnecessary. Virus grown in mammalian cell culture is identical to 
the original clinical isolates. Growth of viruses in eggs result in antigenic variants 
that are distinct from the original virus. The cell culture vaccine more accurately 
matches the wild circulating virus (Giaxo SmithKiine [GSK], n.d.). Another 
considerable advantage of the cell-based technology is the ability to ramp up 
production fairly quickly in times of need. The cell cultures can be frozen for 
future use. 
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Research and public health recommendations. Obviously research into 
the development of new influenza vaccine is important and is already underway. 
While the egg-based technology is well established. cost-effective and proven to 
produce effective vaccine, there are disadvantages (GSK). The goal of 
eliminating these issues fosters further research and development. Until these 
new methods are developed and established, strategies to assure an adequate 
influenza vaccine supply must be addressed as well as contingency plans for 
another vaccine shortage. 
Halloran and Longini (2004) suggest research is needed to 
determine whether increased influenza vaccine coverage in schoolchildren would 
reduce overall influenza attack and death rates in the community as a whole. 
This kind of data could guide vaccine rationing in times of shortfall and also· 
inform public education and marketing techniques for influenza prevention. 
Mayo and Cobler (2004) identify the need for a comprehensive study to 
compare motivators, barriers and decision making of vaccinated versus 
unvaccinated patients. Again, this would be useful information for designing 
promotional programs as well as helping clinicians educate clients and their 
colleagues. 
Decisions will have to be made on the best method to assure an adequate 
yearly supply of influenza vaccine. Should the government provide the industry 
with tax incentives or subsidies in order to avoid the shortages that have 
occurred? Some of the proposals presented by legislators and others prefer that 
the government begin to manufacture and distribute the vaccine to avoid the 
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market forces that have contributed to the departure of influenza vaccine 
manufacturers from the market. Perhaps there should be a compromise as in 
Canada, which has two sources of influenza vaccine, the government supplied at 
no cost to high-risk persons and privately supplied vaccine for pay for all others 
(Boehm). At the least, there must be both public and private investment in 
manufacturing surge capacity and partnerships to more efficiently and effectively 
serve the public. A report by the United States Government Accountability Office 
(GAO) on the vaccine shortage of 2004-2005 concluded that, "planning, timely 
action, and communication are key to an effective response" (GAO, 2005, p.23). 
Lessons learned from the influenza vaccine crisis will enable public health 
agencies from the local to the federal level to develop communication and 
emergency response plans to deal with a similar situation in the future. 
Conclusions. Achieving the goal of high levels of influenza vaccine 
coverage will backfire if there is not a consistently adequate, timely, and 
accurately distributed supply of influenza vaccine. Conversely, increased 
demand for influenza vaccine will enable vaccine manufacturers to profit from 
vaccine manufacturing and provide incentive for continued private and public 
investment in the industry. In addition, advances in influenza vaccine technology 
and production are an integral component of planning for an impending influenza 
pandemic response. 
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